Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: A single-center, retrospective analysis

Pharmacotherapy

Volumn 24, Issue 10 II, 2004, Pages 1323-1330

  Gabardi, Steven ^a,b   Magee, Colm C ^a,c   Baroletti, Steven A ^a   Powelson, John A ^a,c   Cina, Jennifer L ^a   Chandraker, Anil K ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cytomegalovirus; Ganciclovir; Renal transplant; Solid organ transplantation; Valganciclovir

Indexed keywords

ACICLOVIR; ANTACID AGENT; ATOVAQUONE; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; DACLIZUMAB; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DEATH; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PROPHYLAXIS; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 4644339105     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.14.1323.43152     Document Type: Article

References (30)

1. van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 2001;33(suppl 1):s33-7.
2. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7.
3. Sai IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid transplant recipients. Clin Microbiol Rev 2000;13:83-121.
4. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741-51.
5. Stratta RJ. Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation. Transplantation Proc 1993;25(suppl 4):15-21.
6. Jeejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. Transplantation 1998;65:1645-8.
7. Pouria S, State OI, Wong W, Hendry BM. CMV infection is associated with transplant renal artery stenosis. Q J Med 1998;91(3):185-9.
8. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation [editorial]. JAMA 1989;261:3607-9.
9. Das A. Cytomegalovirus infection in solid-organ transplantation. Pharmacoeconomics 2003:21(7):467-75.
10. Henderson R, Carlin D, Kohihase K, Leader S. Multicenter US study of hospital resource utilization associated with cytomegalovirus related readmission of renal and heart transplant patients. Transplant Infect Dis 2001;3(suppl 2):57-9.
11. Wreghitt TG, Abel SJ, McNeil K, et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transplant Int 1999;12(4):254-60.
12. Rubin RH, Tolkoff-Rubin NE, Oliver AV, et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus disease after transplantation. Transplantation 1985;40(3):243-9.
13. Cantarovich D, LeMauff B, Hourmant M, et al. Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin. Transplantation Proc 1989;21:1769-71.
14. Hourmant M, Bedrossian J, Durand D, et al. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment of first kidney transplantation. Transplantation 1996;62:1565-70.
15. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999;39:800-4.
16. Pescovitz MD. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transplant Infect Dis 1999;(suppl 1):31-4.
17. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000;44(10):2811-15.
18. Roche Laboratories, Inc. Valcyte (valganciclovir hydrochloride tablets) prescribing information. Nutley, NJ; 2003.
19. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplantation 2003;3(6):731-5.
20. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplantation 2004;4(4):611-20.
21. Naranjo CA, Busto J, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
22. Akalin E, Bromberg JS, Sehgal V, Ames S, Daly L, Murphy B. 6 months valganciclovir prophylaxis significantly reduces cytomegalovirus infection incidence in thymoglobulin treated transplant patients [abstr]. Am J Transplantation 2004;4(S8):495.
23. SangStat Medical Corporation. Thymoglobulin (anti-thymocyte globulin [rabbit]) prescribing information. Fremont, CA; 2002.
24. Buchler M, Hurault de Ligny B, Madec C, Lebranchu Y, for the French Thymoglobuline Pharmacovigilance Study Group. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplantation 2003;17(6):539-45.
25. Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004;77(7):1029-33.
26. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997;64(12):1843-6.
27. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346(8967):69-74.
28. Baliga RS, Kadambi PV, Javaid B, et al. A nationwide survey of cytomegalovirus prophylaxis and treatment in the transplant community [abstr]. Am J Transplantation 2004;4(S8):495.
29. Zamora MR, Nicolls M, Weill D, et al. Valganciclovir for the prevention of cytomegalovirus following lung transplantation: efficacy and optimal length of therapy [abstr]. Am J Transplantation 2003;3(S5):158.
30. Murray L, ed. Rx product listing. In: 2004 drug topics red book. Montvale, NJ: Thomson PDR, 2004:600.